Celyad
Celyad is a biopharmaceutical company that develops and commercializes cell-based immunotherapies for the treatment of cancer.
Business Model:
Revenue: $6.1k
Employees: 51-200
Industries / Tags:
Detailed Celyad Information
Geographic Data
Address: Rue Edouard Belin 2
City: Mont-Saint-Guibert
State: walloon brabant
Zip: 1435
Country: BE
Financial Info
Stage:
post ipo equity
Raised Last:
$32M
Raised Total:$146M
Social
Metrics
5,977,608Website Global Rank
1,303Website Monthly Traffic
Twitter Followers
Description
Celyad is a biopharmaceutical company that develops and commercializes cell-based immunotherapies for the treatment of cancer.
Contact Phone:
+13210394100
Contact Email:
Celyad went public on 6/19/2015 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
6/19/2015
Ticker Symbol:
CYAD
Amount Raised:
$100M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 11/2019 | Grant | $2.7M | 12/2021 | Private Placement | $32.5M | 2/2015 | Private Placement | $36.2M | 6/2014 | Private Placement | $34.1M | 6/2015 | IPO | $100.1M |
|
5/2013 | Venture Round | 2 | $25M |
Grifols Hunza Ventures Grifols Hunza Ventures |
9/2019 | Post-IPO Equity | $20M | 1/2009 | Series B | $0 |
Grifols Hunza Ventures Life Sciences Research Partners V.Z.W. Grifols Hunza Ventures Life Sciences Research Partners V.Z.W. |
5/2018 | Post-IPO Equity | $47.3M | 12/2019 | Post-IPO Equity | $2.5M | 11/2019 | Grant | $9.4M | 12/2021 | Post-IPO Equity | 1 | $32.5M |
Fortress Investment Group Fortress Investment Group |
8/2007 | Series A | 1 | - |
S.R.I.W. S.R.I.W. |
12/2021 | Post-IPO Equity | 1 | $32.5M |
Fortress Investment Group Fortress Investment Group |
11/2019 | Grant | $9.4M | 5/2018 | Post-IPO Equity | $47.3M | 5/2013 | Venture Round | 2 | $25M |
Hunza Ventures Grifols Hunza Ventures Grifols |
1/2009 | Series B | 3 | $9.5M |
Life Sciences Research Partners V.Z.W. Hunza Ventures Grifols Life Sciences Research Partners V.Z.W. Hunza Ventures Grifols |
8/2007 | Series A | 1 | - |
S.R.I.W. S.R.I.W. |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 6/2016 | Biological Manufacturing Services | |
| 1/2015 | OnCyte | |
| 11/2014 | CorQuest Medical |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
